Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Synthon opens state-of-the-art laboratory for biotechnology

Synthon opened its state-of-the-art laboratory for biotechnology today, an important step in the company’s development into a ‘specialty pharmaceutical’ firm. Ms. Renée Bergkamp, Director-General of Enterprise and Innovation of the Ministry of Economic Affairs, Agriculture and Innovation, and Mr. Thom de Graaf, Mayor of Nijmegen, attended the official opening.

22 May 2011

Global scientists rebuke coming decision on carcinogenicity of radiofrequency and microwaves

In collaboration with the International EMF Alliance (IEMFA), scientists from Europe, North America, Australia and Israel have sent an Open Letter to Dr. Christopher Wild, Director of the International Agency for Research on Cancer (IARC), calling for a postponement of the forthcoming meeting May 24-31, 2011 in Lyon, France, “Non-Ionizing Radiation, Part II: Radiofrequency Electromagnetic Field [includes mobile telephones],” at which determination of the carcinogenicity of cell phones and wireless technologies will be made.

22 May 2011

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.

21 May 2011

Wills Eye Institute and Thomas Jefferson University create new vision research center

A new vision research center based in Philadelphia will foster regional, national and global collaborations among a diverse group of exceptional clinicians and researchers working to better diagnose, treat and prevent visual diseases.

21 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin and SGN-75 programs will be reported at the upcoming American Society of Clinical Oncology 2011 Annual Meeting being held June 3-7, 2011 in Chicago, IL.

21 May 2011

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

21 May 2011

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

A technology that could allow cancer specialists to better determine the most effective chemotherapy treatment for a given patient won the $10,000 in first prize money in the 11th annual Big Bang! Business Plan Competition at the University of California, Davis. The contest is run by MBA students in the Graduate School of Management.

20 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.

20 May 2011

North Shore-LIJ implements new program to ensure safe radiation therapy

Radiation oncologists took a blow in a series of front-page newspaper stories published last year on injuries that occurred nationwide in the delivery of radiation treatment. Radiation oncologists at North Shore-LIJ Health System responded to the public charge with a series of steps that will ensure that patients are protected at all points in the treatment process.

20 May 2011

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived from the Indian spice curcumin can help cells overcome that resistance.

20 May 2011

RTOG reports on largest trial for newly diagnosed glioblastoma

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.

20 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

Study: Costs get in way of cancer patients refilling their prescriptions

About 10 percent of cancer patients aren't taking the oral medicines they need either because of the cost or they feel they are already taking too many other drugs, according to a study released by health-care consulting company Avalere Health late Wednesday.

20 May 2011

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.

20 May 2011

$Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma$

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Viewpoints: Coburn on his dropout; Malpractice reform and states

For the past several months I have been meeting with a small group of senators from both parties, informally known as the Gang of Six, that was designed to force the idle — not gridlocked — Senate, and then the House and the president, to enact a long-term deficit-reduction package.

20 May 2011

Oncology News and Research

Further Reading

Synthon opens state-of-the-art laboratory for biotechnology

Global scientists rebuke coming decision on carcinogenicity of radiofrequency and microwaves

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Wills Eye Institute and Thomas Jefferson University create new vision research center

FDA approves SUTENT for treatment of pancreatic NET

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

North Shore-LIJ implements new program to ensure safe radiation therapy

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

RTOG reports on largest trial for newly diagnosed glioblastoma

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Study: Costs get in way of cancer patients refilling their prescriptions

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Viewpoints: Coburn on his dropout; Malpractice reform and states

Event guide: The 9th DDR Inhibitors Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News